333 related articles for article (PubMed ID: 9791143)
21. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis.
Charalambous D; O'Brien PE
J Gastroenterol Hepatol; 1996 Apr; 11(4):307-10. PubMed ID: 8713695
[TBL] [Abstract][Full Text] [Related]
22. Aberrant crypt foci in the human colon: frequency and histologic patterns in patients with colorectal cancer or diverticular disease.
Nascimbeni R; Villanacci V; Mariani PP; Di Betta E; Ghirardi M; Donato F; Salerni B
Am J Surg Pathol; 1999 Oct; 23(10):1256-63. PubMed ID: 10524527
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans.
Rudolph RE; Dominitz JA; Lampe JW; Levy L; Qu P; Li SS; Lampe PD; Bronner MP; Potter JD
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):605-8. PubMed ID: 15767337
[TBL] [Abstract][Full Text] [Related]
24. Glutathione-S-transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid.
Nobuoka A; Takayama T; Miyanishi K; Sato T; Takanashi K; Hayashi T; Kukitsu T; Sato Y; Takahashi M; Okamoto T; Matsunaga T; Kato J; Oda M; Azuma T; Niitsu Y
Gastroenterology; 2004 Aug; 127(2):428-43. PubMed ID: 15300575
[TBL] [Abstract][Full Text] [Related]
25. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening.
Hüneburg R; Lammert F; Rabe C; Rahner N; Kahl P; Büttner R; Propping P; Sauerbruch T; Lamberti C
Endoscopy; 2009 Apr; 41(4):316-22. PubMed ID: 19340735
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression.
Wargovich MJ; Jimenez A; McKee K; Steele VE; Velasco M; Woods J; Price R; Gray K; Kelloff GJ
Carcinogenesis; 2000 Jun; 21(6):1149-55. PubMed ID: 10837003
[TBL] [Abstract][Full Text] [Related]
27. The natural history of aberrant crypt foci.
Schoen RE; Mutch M; Rall C; Dry SM; Seligson D; Umar A; Pinsky P
Gastrointest Endosc; 2008 Jun; 67(7):1097-102. PubMed ID: 18178205
[TBL] [Abstract][Full Text] [Related]
28. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.
Takayama T; Nagashima H; Maeda M; Nojiri S; Hirayama M; Nakano Y; Takahashi Y; Sato Y; Sekikawa H; Mori M; Sonoda T; Kimura T; Kato J; Niitsu Y
Clin Cancer Res; 2011 Jun; 17(11):3803-11. PubMed ID: 21385928
[TBL] [Abstract][Full Text] [Related]
29. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon.
Wargovich MJ; Chen CD; Harris C; Yang E; Velasco M
Int J Cancer; 1995 Feb; 60(4):515-9. PubMed ID: 7829266
[TBL] [Abstract][Full Text] [Related]
31. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
[TBL] [Abstract][Full Text] [Related]
32. K-ras and p53 mutations in human colorectal aberrant crypt foci.
Losi L; Roncucci L; di Gregorio C; de Leon MP; Benhattar J
J Pathol; 1996 Mar; 178(3):259-63. PubMed ID: 8778329
[TBL] [Abstract][Full Text] [Related]
33. Chemopreventive effect of a probiotic preparation on the development of preneoplastic and neoplastic colonic lesions: an experimental study.
Marotta F; Naito Y; Minelli E; Tajiri H; Bertuccelli J; Wu CC; Min CH; Hotten P; Fesce E
Hepatogastroenterology; 2003; 50(54):1914-8. PubMed ID: 14696432
[TBL] [Abstract][Full Text] [Related]
34. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer.
Stevens RG; Swede H; Heinen CD; Jablonski M; Grupka M; Ross B; Parente M; Tirnauer JS; Giardina C; Rajan TV; Rosenberg DW; Levine J
Cancer Lett; 2007 Apr; 248(2):262-8. PubMed ID: 16950561
[TBL] [Abstract][Full Text] [Related]
35. Age-dependent susceptibility to azoxymethane-induced and spontaneous tumorigenesis in the Min/+ mouse.
Paulsen JE; Steffensen IL; Namork E; Eide TJ; Alexander J
Anticancer Res; 2003; 23(1A):259-65. PubMed ID: 12680222
[TBL] [Abstract][Full Text] [Related]
36. Colonic aberrant crypts in children with familial adenomatous polyposis.
Drut R
Int J Surg Pathol; 2007 Jul; 15(3):258-61. PubMed ID: 17652532
[TBL] [Abstract][Full Text] [Related]
37. Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer.
Konstantakos AK; Siu IM; Pretlow TG; Stellato TA; Pretlow TP
Gastroenterology; 1996 Sep; 111(3):772-7. PubMed ID: 8780584
[TBL] [Abstract][Full Text] [Related]
38. Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid.
Magnuson BA; Carr I; Bird RP
Cancer Res; 1993 Oct; 53(19):4499-504. PubMed ID: 8402621
[TBL] [Abstract][Full Text] [Related]
39. Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.
Takahashi M; Mutoh M; Kawamori T; Sugimura T; Wakabayashi K
Carcinogenesis; 2000 Jul; 21(7):1319-27. PubMed ID: 10874009
[TBL] [Abstract][Full Text] [Related]
40. Modulation of aberrant crypt foci by dietary fat and caloric restriction: the effects of delayed intervention.
Lasko CM; Bird RP
Cancer Epidemiol Biomarkers Prev; 1995; 4(1):49-55. PubMed ID: 7894324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
